The LynxDx leadership team. In the front row (from left to right) are: Spencer Heaton, Chief Medical and Commercial Officer; Steve Riggs, President; and Jeff Crays, Chief Technology Officer. In the ...
Early detection of prostate cancer remains a major clinical challenge due to the lack of reliable biomarkers, despite the disease being highly treatable when caught in its early stages. Now, ...
A new study from the UK has suggested a new way to “significantly” reduce prostate cancer deaths. It says that a simple, 10-minute MRI (Magnetic Resonance Imaging) scan can pick up more early-stage ...
SAN DIEGO -- An algorithm-based decision tool eliminated inappropriate prescribing of bone-modifying agents (BMA) in patients with advanced prostate cancer, according to a VA-based study. Prior to ...
The company behind an imaging agent meant to identify prostate cancer said it received FDA approval on Thursday for use in patients with suspected metastasis or recurrence. Lantheus Holdings, Inc.
Hosted on MSN
A True Game-Changer in Prostate Cancer: A Simple Genomic Test Can Tell Us Who Needs Hormone Therapy And Who Doesn’t
If you or a loved one are navigating the journey of prostate cancer, you know that every decision weighs heavily. You’ve likely faced surgery or initial treatments, only to encounter the fear that ...
“With this test, it could be possible to turn the tide on prostate cancer. We have shown that a relatively simple, inexpensive spit test to identify men of European heritage at higher risk due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback